Aligos enters into an exclusive license and research collaboration agreement with merck to discover and develop an oligonucleotide therapy for nash

South san francisco, calif., dec. 07, 2020 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs) today announced that it has entered into an exclusive license and research collaboration agreement with merck, known as msd outside the united states and canada, under which merck and aligos will apply aligos' oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (nash) target and up to one additional target of interest in the cardiometabolic/fibrosis space.
ALGS Ratings Summary
Quant
ALGS Quant Ranking
Sector
Industry
Quant Rating
Quant Score